BackBarinthus Biotherapeutics Plc. Overview

Barinthus Biotherapeutics Plc. Current Assets

Latest current assets for BRNS: $63M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$63.27M
36.99% YoYΔ $-37.14M vs prior year quarter

Peer trimmed avg / median

Loading

Barinthus Biotherapeutics Plc. Current Assets History

Loading

Barinthus Biotherapeutics Plc. vs. peers: Current Assets Comparison

Loading

Barinthus Biotherapeutics Plc. Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Barinthus Biotherapeutics Plc. (BRNS) FAQ

Barinthus Biotherapeutics Plc. (BRNS) currently reports a current assets of $63M as of June 2026. That compares with $100M in the prior-year period — down 37.0% year over year. Use the charts on this page to explore Barinthus Biotherapeutics Plc.'s current assets history and peer comparisons.

Barinthus Biotherapeutics Plc.'s current assets decreased from $100M to $63M — a 37.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Barinthus Biotherapeutics Plc. reported $63M in current assets as of June 2026. That compares with $100M in the prior-year period — down 37.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current assets of $63M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Barinthus Biotherapeutics Plc., and consider following BRNS for alerts when major investors trade the stock.

Barinthus Biotherapeutics Plc. is classified in the Healthcare sector. On current assets, it currently shows $63M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BRNS with unrelated industries.